Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 9/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30457465 | 0.82 | MEN1 (0.76) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL25633524 | 0.82 | MEN1 (0.76) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL25633527 | 0.82 | MEN1 (0.78) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL25633494 | 0.81 | KMT2A (0.50) | MAPTPOLBALDH1A1GAAMEN1 | |
| SCHEMBL25228060 | 0.81 | MAPT (0.79) | MAPTPOLBALDH1A1GAAMEN1 | |
| SCHEMBL123633 | 0.81 | GRK5 (0.56) | MAPTALDH1A1GAAMEN1KMT2A | |
| SCHEMBL25633571 | 0.80 | MEN1 (0.60) | MAPTPOLBALDH1A1GAAMEN1 | |
| SCHEMBL30457791 | 0.77 | MEN1 (0.54) | MAPTPOLBALDH1A1GAAMEN1 | |
| SCHEMBL25633523 | 0.77 | MEN1 (0.54) | MAPTPOLBALDH1A1GAAMEN1 | |
| SCHEMBL28460327 | 0.76 | ALOX5 (0.49) | MAPTPOLBALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | PARIS SCIENCES ET LETTRES (FR) | 2025-02-13 | — | — | US | disclosed |
| EP-4444308-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | Institut Curie (FR) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023104976-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | INSTITUT CURIE (FR) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051314-A1 | SMALL MOLECULE INHIBITORS OF INTERFERON GAMMA SIGNALING | STAT1, IFNG, IRF2BP2 | MAPT 4087/4885POLB 1045/4885ALDH1A1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.